MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	8/9/2008 2:45:12 AM
	of 2240

Johnson & Johnson drug review delayed by 3 months August 8, 2008 NEW BRUNSWICK, N.J.—Johnson & Johnson's Centocor unit said Friday the Food and Drug Administration will take an additional three months to review an application for the experimental psoriasis drug ustekinumab. The company said the review could now run through December. Centocor is seeking approval of the drug for adult patients with chronic moderate to severe plaque psoriasis, a severe skin disease. The FDA extended the review period because of application amendments made over the last three months. In June, an FDA advisory panel unanimously recommended approval. The regulatory agency normally follows the recommendations of its advisory panels, though it is not required to do so.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next